Skip to main content

ICU Medical Inc.

corporate_fare Company Profile

ICU Medical Inc.

ICUI·NASDAQ·Industrial Applications And Services·CIK 0000883984

ICU Medical, Inc. develops, manufactures, and sells medical products for infusion therapy, vascular access, and vital care applications. The company's product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, sharps safety products, and sterile IV solutions offered through a joint venture; closed system transfer devices and pharmacy compounding systems; and respiratory, anesthesia, patient monitoring, and temperature management products. Headquartered in San Clemente, California, ICU Medical was founded in 1984. Its primary customers are acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. The company has expanded through organic growth and acquisitions. In February 2017, ICU Medical acquired Pfizer Inc.'s Hospira Infusion Systems (HIS) business, which expanded its product portfolio to include a complete intravenous infusion therapy product-line from IV solutions to IV pumps to non-dedicated infusion sets. In November 2019, it acquired Pursuit Vascular, Inc., a medical device company focused on catheter disinfecting products, with its primary product being the ClearGuard ® HD cap for hemodialysis catheter maintenance. In January 2022, ICU Medical acquired Smiths Medical 2020 Limited, the global medical device business of Smiths Group plc, which added syringe and ambulatory infusion devices, vascular access, and vital care products.

ICU Medical Inc. (NASDAQ:ICUI) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 10 items for ICUI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-06, rated 8/10. Across its 10 most recent items scored 7 or higher, the top rating is 8/10, with 4 rated 8 or above. Recent SEC coverage for ICUI spans 10-Q, 8-K, DEF 14A, PRE 14A.

Recent high-impact activity:

  • ICU Medical Beats Q2 Estimates, Raises 2026 EPS Guidance by 11%
  • ICU Medical Q2 2026: Gross Margin Surge and Tariff Windfall Offset Restructuring Drag
  • ICU Medical Raises FY2026 Guidance After Q2 Beat; Adjusted EPS $2.37 vs $2.10
  • Stockholders Approve Enhanced Governance: Simple Majority Voting & 25% Special Meeting Right
  • ICU Medical Confirms Q1 Profitability and Margin Gains, Discloses New FDA Warning Letter for Infusion Pumps

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$2.23B
Net Income
$732K
Diluted EPS
$0.03
Op. Cash Flow
$179.85M
Free Cash Flow
$91.8M
Gross Profit
$822.04M
Operating Income
$42.83M
Cash & Equivalents
$307.96M
Total Debt
$1.28B
Debt / Equity
0.60×
Net Margin
0.0%
Shares Outstanding
24.69M sh
Source: 10-K · filed 2026-02-19 · accession 0000883984-26-000008

Short Interest & Short Volume

6.29 days to cover

FINRA reported short interest of 1,515,688 shares in ICUI as of the September 15, 2026 settlement, a 5.8% increase from the prior period — about 6.3 days to cover at its recent average daily volume. On October 2, 2026, 76.5% of ICUI volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,515,688 shares as of September 15, 2026
Change vs prior period▲ 5.8%
Days to cover6.29 at avg daily volume of 241,127
Daily short volume (FINRA facilities)76.5% of 85,734 shares on October 2, 2026
5-day average short volume62.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with I →
$159.38
52-week range · as of 2026-08-06 $107 – $176.27
Market cap
$3.99B
Volume
227.7K (0.9× avg)
3-mo avg 246.1K
Live data · 2026-10-05 02:48 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ICUI - Latest Insights

ICUI
Aug 06, 2026, 4:36 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $174.28
Real-time Price: $159.38 info
Change: -$14.90 (-9%) info
Market Cap: $3.986B info
ICUI
Aug 06, 2026, 4:34 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $174.28
Real-time Price: $159.38 info
Change: -$14.90 (-9%) info
Market Cap: $3.986B info
ICUI
Aug 06, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $174.28
Real-time Price: $159.38 info
Change: -$14.90 (-9%) info
Market Cap: $3.986B info
ICUI
May 18, 2026, 12:35 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $120.89
Real-time Price: $159.38 info
Change: +$38.49 (+32%) info
Market Cap: $3.986B info
ICUI
May 07, 2026, 4:20 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $123.07
Real-time Price: $159.38 info
Change: +$36.31 (+30%) info
Market Cap: $3.986B info
ICUI
May 07, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $123.07
Real-time Price: $159.38 info
Change: +$36.31 (+30%) info
Market Cap: $3.986B info
ICUI
Apr 02, 2026, 4:07 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $123.31
Real-time Price: $159.38 info
Change: +$36.07 (+29%) info
Market Cap: $3.986B info
ICUI
Mar 23, 2026, 4:50 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $129.93
Real-time Price: $159.38 info
Change: +$29.45 (+23%) info
Market Cap: $3.986B info
ICUI
Feb 19, 2026, 4:40 PM EST
Filing Type: 10-K
Importance Score:
7
Price at Filing: $149.74
Real-time Price: $159.38 info
Change: +$9.64 (+6%) info
Market Cap: $3.986B info
ICUI
Feb 19, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $149.74
Real-time Price: $159.38 info
Change: +$9.64 (+6%) info
Market Cap: $3.986B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets